UNSPSC 51381705: Acetaminophen sulfate

This classification denotes an analgesic and antipyretic with the molecular formula C8H9NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6002H6J9F, chemically known as acetamide, n-(4-(sulfooxy)phenyl)-, but more generally known as acetaminophen sulfate, which bears US NIH Compound Identifier 83939. European Medicines Agency schedules acetaminophen sulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09611MIG.

Most nations, for tariff purposes, schedule acetaminophen sulfate under HS 29242990. SMILES: CC(=O)NC1CCC(CC1)OS(=O)(=O)O.

UNSPSC 51381705 Acetaminophen sulfate is a Commodity code that in practice captures state and local procurement of pharmaceutical products, though recent opportunities under this code span a broader range of drugs and delivery mechanisms than the code name alone suggests. State and local health agencies, counties, and multistate cooperative purchasing alliances are buying naloxone, generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment capabilities. The work involves sourcing finished pharmaceutical products from manufacturers and wholesalers, meeting FDA and cGMP compliance, managing supply chain security under the Drug Supply Chain Security Act, and ensuring products reach public health facilities, community health programs, and state employee health plans with specified shelf life and expiration requirements.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). Recent activity centers on Florida, Texas, and the Upper Midwest. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). Vendors in this space face strict insurance requirements (commercial general liability of up to $5 million per occurrence), EDI and data format compliance, wholesaler relationships, and administrative fee structures—with MMCAP's contract weighted 75 percent on price competitiveness and 25 percent on administrative factors including cGMP certification and pricing flexibility.